Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 22

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 22
---
 and initiate clinical trials. In addition, if we obtain regulatory approval for any programs, we expect to incur
significant expenses related to production of sales, marketing, and distribution to the extent that such sales, marketing and distribution
are not the responsibility of potential collaborators. We expect to incur additional costs associated with operating as a public company.

We
had net losses of $1.1 million and $6.0 million for the three months ended September 30, 2025 and 2024, respectively and $8.4 million
and $13.7 million for the nine months ended September 30, 2025 and 2024, respectively.

Highlights
– Three Months Ended September 30, 2025 and beyond

●
On May 19, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an agreement to raise $3 million in equity financing
through a direct investment by The Bayshore Trust, an entity affiliated with the Company’s largest shareholder. The transaction
was structured as a straight restricted common stock deal with no warrants. The Company issued 333,334 restricted shares of its common
stock, no par value (the “Common Stock”) at a purchase price of $3.00 per share, representing an 18% premium to the closing
share price of the Common Stock of $2.54 on the date of execution (the “Bayshore Financing”). The Company received the initial
payment of $1 million for the Bayshore Financing on May 20, 2025. On July 24, 2025, an additional $2 million was received, for the issuance
of 666,666 shares.

●
On July 17, 2025, we reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, in a murine xenograft
model using P3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of
the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner.

●
On July 18, 2025, we sold a total of 1,100,000 shares of our common stock, no par value, in block sales to institutional investors, at
an average price of $2.6045 per share (a premium to the prior day’s close), through its at-the-market equity offering facility.

15

●
On July 23